Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $15.3 million, up from $8 million in Q2 2024, primarily due to variability in Pharma Biocatalysis customers' manufacturing schedules and clinical trial progression [14][15] - Product gross margin increased to 72% in Q2 2025 from 45% in Q2 2024, attributed to shifts in sales to more profitable products [15][17] - The net loss for Q2 2025 was $13.3 million, compared to $22.8 million in Q2 2024, indicating improved financial performance [17] Business Line Data and Key Metrics Changes - The Pharma Biocatalysis business saw increased orders for enzymes supporting late-phase and commercialized APIs, contributing to strong Q2 revenue [6][14] - The Ecosynthesis platform is experiencing strong customer engagement, with over 30 ongoing customer engagements, indicating growing demand [5][21] Market Data and Key Metrics Changes - The demand for the Ecosynthesis platform is expected to exceed supply, prompting the company to explore options to expand capacity [5][12] - The ligation process is becoming the new standard in siRNA manufacturing, with the company focusing on acquiring new ligase customers [9][10] Company Strategy and Development Direction - The company aims to achieve cash flow breakeven by 2026 while exploring ways to maximize stockholder value through the Ecosynthesis platform [4][5] - A strategy is in place to secure early-phase products on the ECO platform, which could lead to significant returns as these products mature into commercial drugs [5][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory towards profitability and highlighted the importance of managing expenses while capitalizing on the strong cash position [17] - The company anticipates continued revenue lumpiness in the near term due to the unpredictability of the heritage business, but expects growth from the Ecosynthesis platform in the coming years [15][30] Other Important Information - The company ended the quarter with $66.3 million in cash and equivalents, sufficient to fund operations through 2027 [18] - Management is focused on establishing a GMP facility to improve the scale-up process and service small to medium-sized drug innovators [12][34] Q&A Session Summary Question: Can you provide an update on the pipeline and customer discussions? - The company has over 30 discussions ongoing, potentially growing into the 40s, with a mix of CDMOs and biopharma companies [21][22] Question: What is the status of process development projects in the Eco Innovation Lab? - The company is excited about recruiting early-phase projects and is considering setting up a second Eco Lab to increase capacity [27][28] Question: How does the company plan to expand bandwidth for the ECO platform? - The focus is on filling existing capacity and exploring partnerships while ensuring a credible path to GMP material [33][35] Question: What is the company's IP position around Ecosynthesis? - The company has a strong IP portfolio and emphasizes the importance of trade secrets and know-how in maintaining a competitive edge [37][38] Question: How should investors think about revenue collection pace? - The company aims to lock in a large number of early-stage projects, which could lead to significant future revenues as these assets mature [42][46] Question: What are the options for funding scaling to GMP? - The company is not considering selling its biocatalysis business, as it is profitable and reduces cash needs, while also planning incremental scaling [68][69]

Q2 2025 Financial Performance - Total revenue increased to $15.3 million, compared to $8.0 million in Q2 2024[11] - Product gross margin improved significantly to 72% from 45% in Q2 2024[11] - Loss from operations decreased to ($12.9) million from ($22.7) million year-over-year[11] - Net loss per share improved to ($0.16) from ($0.32) year-over-year[11] Business Highlights - The company is experiencing growing momentum with ECO Synthesis, with 34 ongoing customer engagements[7] - Customers are bringing their most complex manufacturing challenges to Codexis, indicating strong demand for their solutions[10] - Chemo-enzymatic route (ligation) is becoming the new standard in siRNA manufacturing, benefiting the company's ligase business[10] Strategic Focus - The company is shifting emphasis to newer assets with longer runway and better economics[7] - The company is exploring the development of a Codexis-owned GMP facility[10] - The company continues to carefully manage burn rate and reiterates 2025 guidance range[13]

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents unaudited condensed consolidated financial statements, highlighting increased Q2 2025 revenue, narrowed net loss, and substantial cash inflow from financing activities [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $138.2 million by June 30, 2025, from $149.0 million, driven by reduced short-term investments, while equity also declined Condensed Consolidated Balance Sheets | Financial Metric | June 30, 2025 ($ in thousands) | December 31, 2024 ($ in thousands) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | 26,761 | 19,264 | | Short-term investments | 39,569 | 54,194 | | Total current assets | 88,729 | 98,772 | | Total assets | 138,246 | 149,011 | | **Liabilities & Equity** | | | | Total current liabilities | 15,237 | 23,648 | | Long-term debt | 39,373 | 28,905 | | Total liabilities | 82,615 | 82,084 | | Total stockholders' equity | 55,631 | 66,927 | [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q2 2025 total revenues nearly doubled to $15.3 million, driven by R&D, significantly narrowing net loss to $13.3 million from $22.8 million Condensed Consolidated Statements of Operations | Metric ($ in thousands, except EPS) | Q2 2025 | Q2 2024 | Six Months 2025 | Six Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Total Revenues | 15,328 | 7,979 | 22,871 | 25,052 | | Product Revenue | 7,380 | 6,259 | 13,439 | 15,810 | | R&D Revenue | 7,948 | 1,720 | 9,432 | 9,242 | | Loss from Operations | (12,862) | (22,732) | (33,348) | (34,620) | | Net Loss | (13,272) | (22,755) | (33,960) | (34,260) | | Net Loss per Share | (0.16) | (0.32) | (0.40) | (0.49) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations increased to $31.8 million, while investing activities provided $11.4 million, and financing provided $27.9 million Condensed Consolidated Statements of Cash Flows | Cash Flow Activity ($ in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | (31,765) | (19,957) | | Net cash provided by (used in) investing activities | 11,402 | (55,650) | | Net cash provided by financing activities | 27,859 | 29,084 | | **Net change in cash, cash equivalents & restricted cash** | **7,496** | **(46,523)** | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail revenue by geography, the $40 million Innovatus Loan, $16.4 million from equity sales, and significant customer concentration - For the six months ended June 30, 2025, the Americas and APAC regions were the largest sources of revenue, contributing **$8.4 million** and **$8.1 million**, respectively[39](index=39&type=chunk) - The company entered into a five-year term loan agreement with Innovatus for up to **$40.0 million**, with the second tranche of **$10.0 million** funded in June 2025[74](index=74&type=chunk) - During Q2 2025, the company sold 7,244,966 shares of common stock under its Cantor Sales Agreement, receiving net proceeds of **$16.4 million**[67](index=67&type=chunk) - Customer concentration remains high, with Customer A and Customer B accounting for **21%** and **19%** of total revenues, respectively, for the three months ended June 30, 2025[82](index=82&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses strategic focus on pharma biocatalysis and ECO Synthesis™, highlighting a 92% Q2 revenue increase, improved gross margin, and sufficient liquidity [Business Overview](index=22&type=section&id=Business%20Overview) Codexis leverages its CodeEvolver® platform for pharma biocatalysis and develops the ECO Synthesis™ platform for RNAi therapeutics manufacturing - The company's core strategy revolves around its proprietary CodeEvolver® directed evolution technology platform to develop novel enzymes[85](index=85&type=chunk) - Key focus areas are the established pharma biocatalysis business and the emerging Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ manufacturing platform for RNAi therapeutics[85](index=85&type=chunk) - In 2025, the company expects to manufacture GLP-grade siRNA for customers in its Innovation Lab and partner with a CDMO for GMP-grade synthesis using the ECO Synthesis™ platform[87](index=87&type=chunk) [Results of Operations](index=23&type=section&id=Results%20of%20Operations) Q2 2025 total revenues surged 92% to $15.3 million, driven by R&D, with product gross margin improving to 72% and SG&A expenses decreasing 21% Results of Operations Summary | Metric ($ in thousands) | Q2 2025 | Q2 2024 | Change $ | Change % | | :--- | :--- | :--- | :--- | :--- | | Total Revenues | 15,328 | 7,979 | 7,349 | 92% | | Product Revenue | 7,380 | 6,259 | 1,121 | 18% | | R&D Revenue | 7,948 | 1,720 | 6,228 | 362% | | Cost of Product Revenue | 2,098 | 3,462 | (1,364) | (39)% | | Product Gross Margin | 72% | 45% | - | - | - The increase in Q2 R&D revenue was driven by **$3.6 million** from legacy agreements and **$2.5 million** from a new licensing agreement executed in the quarter[95](index=95&type=chunk) - SG&A expenses decreased by **$3.4 million** in Q2 2025 compared to Q2 2024, mainly due to **$2.2 million** in lower stock-based compensation and **$0.9 million** in lower legal costs[102](index=102&type=chunk) [Liquidity and Capital Resources](index=27&type=section&id=Liquidity%20and%20Capital%20Resources) The company holds $66.3 million in cash and investments, supported by a $40 million term loan and equity sales, deemed sufficient for 12 months Liquidity and Capital Resources Summary | Metric ($ in thousands) | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | 26,761 | 19,264 | | Short-term investments | 39,569 | 54,194 | | Working capital | 73,492 | 75,124 | - The company secured a five-year term loan from Innovatus for up to **$40 million**, with the full amount drawn as of June 27, 2025[112](index=112&type=chunk)[116](index=116&type=chunk) - Under the Cantor Sales Agreement, the company raised gross proceeds of **$17.3 million** during Q2 2025[117](index=117&type=chunk) - Management believes existing cash and expected revenues will provide adequate funds for operations for at least the next 12 months[119](index=119&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=30&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company faces interest rate and foreign currency risks, but a hypothetical 10% adverse change is not expected to materially impact its financial position - As of June 30, 2025, the company had **$66.3 million** in cash, cash equivalents, and short-term investments subject to interest rate risk[128](index=128&type=chunk) - The company has **$40.8 million** in principal outstanding under the variable-rate Innovatus Loan, where a 10% increase in the prime rate would impact results by **$0.3 million** over the next twelve months[129](index=129&type=chunk) - Foreign currency risk is considered minimal, with a hypothetical 10% unfavorable change in exchange rates resulting in a potential loss of approximately **$40 thousand**[130](index=130&type=chunk) [Item 4. Controls and Procedures](index=31&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including CEO and CFO, deemed disclosure controls effective as of June 30, 2025, with no material changes to internal controls - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of the end of the period covered by this report[134](index=134&type=chunk) - No material changes to the company's internal control over financial reporting were identified during the most recent fiscal quarter[135](index=135&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=32&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any material pending litigation or other legal proceedings - As of the filing date, Codexis is not involved in any material legal proceedings[138](index=138&type=chunk) [Item 1A. Risk Factors](index=32&type=section&id=Item%201A.%20Risk%20Factors) This section outlines key risks including net losses, customer and manufacturer dependence, unproven ECO Synthesis platform, competition, and financial and regulatory risks - **Financial & Strategic Risks:** The company has a history of net losses and may not achieve profitability, is dependent on a limited number of customers, and its new ECO Synthesis platform is based on novel, largely unproven technology[140](index=140&type=chunk)[142](index=142&type=chunk)[163](index=163&type=chunk) - **Operational Risks:** Codexis relies on a limited number of third-party contract manufacturers for large-scale production of its enzymes, posing a risk to supply chain stability[140](index=140&type=chunk)[157](index=157&type=chunk) - **Capital & Debt Risks:** The company may need additional capital in the future and must comply with covenants in its loan agreement with Innovatus, which could restrict business operations[141](index=141&type=chunk)[185](index=185&type=chunk)[187](index=187&type=chunk) - **Regulatory & IP Risks:** The company's and its customers' products are subject to extensive regulation, and protecting its intellectual property rights is critical and may involve costly litigation[141](index=141&type=chunk)[143](index=143&type=chunk)[208](index=208&type=chunk) [Other Items (Items 2, 3, 4, 5, 6)](index=60&type=section&id=Other%20Items) This section covers remaining disclosures, including no unregistered equity sales, no defaults, no Rule 10b5-1 plan changes, and a list of exhibits - There were no unregistered sales of equity securities during the period[259](index=259&type=chunk) - During the three months ended June 30, 2025, no directors or executive officers adopted or terminated any Rule 10b5-1 trading arrangements[262](index=262&type=chunk)

[Business and Strategic Update](index=1&type=section&id=Business%20and%20Strategic%20Update) Codexis reported strong Q2 2025 revenue, emphasizing ECO Synthesis® platform momentum and securing $27.3 million for expansion - The CEO highlighted a strategic shift with strong external validation for the ECO Synthesis® platform, noting over **30 ongoing opportunities** and a targeted fundraising to support growth and the development of **GMP-grade siRNA**[2](index=2&type=chunk) - The company strengthened its cash position by raising a total of **$27.3 million** from its at-the-market (ATM) facility and a loan agreement with Innovatus Capital Partners, LLC[1](index=1&type=chunk)[4](index=4&type=chunk) - The ECO Synthesis® platform received significant industry validation at the **TIDES USA Annual Meeting**, with presentations from CDMOs like Bachem, Nitto Avecia, and ST Pharm confirming the technology's transferability[2](index=2&type=chunk)[4](index=4&type=chunk) - **Cynthia Collins**, an expert in the CDMO landscape, was appointed to the **Board of Directors**, strengthening the company's strategic oversight[4](index=4&type=chunk) [Second Quarter 2025 Financial Highlights](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Highlights) Codexis achieved $15.3 million in Q2 2025 revenues, improving product gross margin to 72% and narrowing net loss Q2 2025 vs Q2 2024 Financial Performance | Financial Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | Total Revenues | $15.3 million | $8.0 million | +91.6% | | Product Gross Margin | 72% | 45% | +27 p.p. | | R&D Expenses | $13.8 million | $11.4 million | +21.1% | | SG&A Expenses | $12.3 million | $15.7 million | -21.7% | | Net Loss | $13.3 million | $22.8 million | Improved | | Net Loss Per Share | $0.16 | $0.32 | Improved | - The increase in total revenues was primarily attributed to the variability in customers' manufacturing schedules, clinical trial progression, higher revenue from legacy agreements, and a new licensing agreement[7](index=7&type=chunk) - As of June 30, 2025, the company maintained a cash, cash equivalents, and short-term investments balance of **$66.3 million**[7](index=7&type=chunk) [Upcoming Milestones](index=2&type=section&id=Upcoming%20Milestones) Codexis outlined key 2025 milestones: TIDES Europe presentation, pilot-scale GLP-grade siRNA, and GMP scale-up partner - Key upcoming milestones for 2025 include: - Presenting at the **TIDES Europe Annual Meeting** in November - Achieving pilot scale production of **GLP-grade siRNA material** via the ECO Synthesis Innovation Lab - Signing a **GMP scale-up partner** by year-end to enable larger scale siRNA production[7](index=7&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) This section presents unaudited consolidated financial statements: Operations, Comprehensive Loss, and Balance Sheets [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Total revenues nearly doubled to $15.3 million in Q2 2025, reducing loss from operations and net loss Condensed Consolidated Statements of Operations (In Thousands, Except Per Share Amounts) | | Three Months Ended June 30, | Six Months Ended June 30, | | :--- | :--- | :--- | :--- | :--- | | | **2025** | **2024** | **2025** | **2024** | | **Total revenues** | **$15,328** | **$7,979** | **$22,871** | **$25,052** | | Product revenue | $7,380 | $6,259 | $13,439 | $15,810 | | Research and development revenue | $7,948 | $1,720 | $9,432 | $9,242 | | **Total costs and operating expenses** | **$28,190** | **$30,711** | **$56,219** | **$59,672** | | Cost of product revenue | $2,098 | $3,462 | $4,830 | $8,317 | | Research and development | $13,775 | $11,413 | $26,717 | $22,659 | | Selling, general and administrative | $12,317 | $15,671 | $24,672 | $28,531 | | **Loss from operations** | **$(12,862)** | **$(22,732)** | **$(33,348)** | **$(34,620)** | | **Net loss** | **$(13,272)** | **$(22,755)** | **$(33,960)** | **$(34,260)** | | **Net loss per share, basic and diluted** | **$(0.16)** | **$(0.32)** | **$(0.40)** | **$(0.49)** | [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets were $138.2 million, cash $66.3 million, liabilities $82.6 million, and equity $55.6 million Condensed Consolidated Balance Sheet Highlights (In Thousands) | | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $26,761 | $19,264 | | Short-term investments | $39,569 | $54,194 | | Total current assets | $88,729 | $98,772 | | **Total assets** | **$138,246** | **$149,011** | | **Liabilities and Stockholders' Equity** | | | | Total current liabilities | $15,237 | $23,648 | | Long-term debt | $39,373 | $28,905 | | **Total liabilities** | **$82,615** | **$82,084** | | **Total stockholders' equity** | **$55,631** | **$66,927** | | **Total liabilities and stockholders' equity** | **$138,246** | **$149,011** | [About Codexis & Forward-Looking Statements](index=3&type=section&id=About%20Codexis%20%26%20Forward-Looking%20Statements) This section provides a corporate overview of Codexis's enzymatic solutions and platforms, with a forward-looking statements disclaimer - Codexis leverages its **CodeEvolver®** technology platform to develop high-performance enzymes for small molecule pharmaceuticals and nucleic acid synthesis, and is currently developing its **ECO Synthesis®** platform for manufacturing **RNAi therapeutics**[8](index=8&type=chunk) - The press release contains **forward-looking statements** concerning anticipated milestones, financial expectations, and the potential of its technology platforms, subject to **risks and uncertainties** detailed in the company's **SEC filings**[9](index=9&type=chunk)

Core Insights - Codexis, Inc. reported revenue of $15.3 million for Q2 2025, exceeding the analyst consensus estimate of $14.1 million, and showing significant growth from $8.0 million in Q2 2024 [1][12] - The company raised $27.3 million through an at-the-market (ATM) facility and a loan from Innovatus to support the expansion of its ECO Synthesis platform [2][7] - Codexis is experiencing a strategic shift with over 30 ongoing engagements related to its ECO Synthesis technology, which is aimed at enhancing the manufacturing of RNAi therapeutics [3][7] Financial Highlights - Total revenues for Q2 2025 were $15.3 million, a 92.5% increase from $7.9 million in Q2 2024 [12] - Product gross margin improved to 72% in Q2 2025 from 45% in Q2 2024, attributed to a shift towards more profitable products [12] - Research and Development expenses rose to $13.8 million in Q2 2025 from $11.4 million in Q2 2024, driven by increased headcount [12] - Selling, General & Administrative expenses decreased to $12.3 million in Q2 2025 from $15.7 million in Q2 2024, mainly due to lower stock-based compensation [12] - The net loss for Q2 2025 was $13.3 million, or $0.16 per share, compared to a net loss of $22.8 million, or $0.32 per share, in Q2 2024 [12] Business Developments - Six presentations at the 2025 TIDES USA annual meeting highlighted the ECO Synthesis platform, showcasing its capabilities in siRNA manufacturing [2][7] - Codexis appointed Cynthia Collins to its Board of Directors, bringing expertise in the CDMO landscape [7] - The company anticipates achieving pilot scale production of GLP-grade siRNA material in 2025 and aims to sign a GMP scale-up partner by the end of 2025 [7][12]

Core Viewpoint - Codexis, Inc. will report its financial results for Q2 2025 on August 13, 2025, and will host a conference call to discuss these results and provide a business update [1]. Company Overview - Codexis is a leading provider of enzymatic solutions aimed at efficient and scalable manufacturing of complex therapeutics, utilizing its proprietary CodeEvolver technology platform [3]. - The company is developing the ECO Synthesis™ manufacturing platform to facilitate the scaled production of RNAi therapeutics through an enzymatic process [3]. - Codexis' enzymes are designed to address challenges in small molecule pharmaceuticals manufacturing and nucleic acid synthesis, offering benefits such as higher yields, reduced energy consumption, and improved manufacturing efficiency [3].

Summary of Codexis Conference Call Company Overview - **Company**: Codexis - **Industry**: Life Sciences, specifically focusing on enzymatic synthesis and RNA technologies Key Points and Arguments Ecosystem Platform Development - Codexis has made significant progress in the last 24 months with its Ecosystems Platform, transitioning from concept to execution of commercial products, particularly in the area of enzymatic synthesis for RNA constructs [2][3] - The company has established a GLP Eco Innovation Lab capable of producing both fragments and full-length RNA molecules through sequential enzymatic synthesis [3][4] Revenue Generation and Contracts - Codexis has secured its first revenue-generating contract associated with the Ecosystems Platform, focusing on manufacturing a novel construct for a third-party pharmaceutical innovator [5] - The company anticipates increasing the scale of production to support the development of this molecule [5] Market Acceptance and Demand - There is a growing acceptance of enzymatic synthesis technology within the industry, with many companies recognizing its advantages as they scale siRNA modalities [3][4] - Codexis is positioned as a leader in this space, with a high success rate in producing requested constructs [4] Customer Engagement and Pipeline - Codexis is engaging with multiple CDMOs and innovators, facilitating discussions on how to integrate their ligase technology into existing processes [9] - The company expects to have four customers purchasing ligase by the end of the year, up from one last year, indicating a strong pipeline [9] Innovation Lab and Economic Model - The Innovation Lab aims to balance larger customers with promising early-phase molecules, focusing on both current market needs and future potential [10][11] - The economic model includes modest upfront fees, shared costs during development, and success milestones, ensuring the lab's viability [12][13] Scaling and Capacity - Codexis plans to build a 50-kilo annual capacity facility cost-effectively, leveraging existing manufacturing infrastructure [16][17] - The facility is expected to be operational within 18 months to two years, significantly faster than traditional methods [20] Onshoring Supply Chains - The company is capitalizing on the trend of onshoring supply chains, offering enzymatic technology to enhance existing facilities and reduce capital expenditures [18][19] Competitive Landscape - Codexis faces competition primarily from CDMOs and companies attempting to improve traditional chemistry methods rather than direct enzymatic synthesis competitors [32][38] - The demand for siRNA is projected to reach 30 metric tons by the end of the decade, with enzymatic synthesis being the preferred method for large-scale production [34][36] Partnerships and Collaborations - The partnership with Aldevron for high-capacity RNA polymerase has been successful, with Aldevron developing a GMP process and gaining commercial traction [41][42] - Codexis is exploring further partnerships with companies like Danaher and SITIVA to enhance its ecosystem [43][44] Financial Outlook - Codexis aims to reach positive cash flow by the end of 2026, supported by its profitable heritage pharma manufacturing business [45][46] - The company is focused on securing real assets and partnerships to validate its growth trajectory [48][49] Conclusion - Codexis is strategically positioned in the life sciences industry, with a strong focus on enzymatic synthesis and RNA technologies. The company is actively expanding its customer base, enhancing its innovation capabilities, and preparing for significant growth in the coming years.

Codexis (CDXS) Conference Call Summary - May 22, 2025 Company Overview - **Company**: Codexis (CDXS) - **Industry**: Biotechnology, specifically focusing on siRNA (small interfering RNA) technology and enzymatic synthesis for genomic medicines Key Points and Arguments Industry Trends - **Surge in Demand for siRNA Therapeutics**: There is a recognized increase in demand for siRNA therapeutics, with significant interest in innovative manufacturing solutions [5][6] - **Shift Towards Enzymatic Synthesis**: The industry is moving towards enzymatic synthesis methods, which are seen as necessary to meet the scalability and purity requirements for siRNA production [6][18] Codexis Technology and Developments - **Ecosynthesis Technology**: Codexis' Ecosynthesis platform is positioned as a timely solution to the limitations of traditional solid-phase chemistry, with advancements in scalability and cost-effectiveness [10][18] - **Validation from Industry Leaders**: Codexis received external validation from major oligonucleotide manufacturers, highlighting the effectiveness of its double-stranded RNA ligase [6][7] - **Machine Learning Tool**: A newly developed machine learning tool aids customers in optimizing RNA fragment designs, demonstrating superior performance in identifying effective solutions [12][41] Customer Engagement and Market Position - **Increased Customer Interest**: There has been a notable shift in customer engagement, with decision-makers in process development now actively exploring Codexis' enzymatic solutions [17][18] - **Growing Customer Base**: The number of substantive discussions with potential customers has increased significantly, from single digits to over 20 prospects [20] - **Innovation Lab Capacity**: Codexis aims to fill its Eco Innovation Lab capacity with multiple customers, focusing on a diverse range of products [35][36] Competitive Landscape - **Leadership in Enzymatic Technology**: Codexis is recognized as a leader in enzymatic technology for siRNA manufacturing, with expectations to maintain this position through continued advancements [21][18] Future Outlook - **Partnerships and Collaborations**: Codexis is on track to sign a GMP scale-up partnership and anticipates selling its Eco Innovation Labs capacity by year-end [20] - **Focus on Stereochemistry Control**: The ability to control stereochemistry in siRNA production is seen as a significant advantage, allowing for the development of more effective therapeutic candidates [31][52] Additional Important Insights - **Transition from Proof of Concept to Production**: Codexis is moving from demonstrating proof of concept to establishing a practical production platform, emphasizing the importance of cycle times in manufacturing [27][28] - **Impact of Stereochemistry on Efficacy**: The control of stereochemistry is crucial for ensuring the activity and effectiveness of siRNA therapeutics, with implications for both existing and new products [50][52] This summary encapsulates the key discussions and insights from the Codexis conference call, highlighting the company's strategic positioning within the biotechnology industry and its advancements in siRNA technology.

Core Insights - Codexis presented its proprietary ECO Synthesis platform at the TIDES USA annual meeting, demonstrating its effectiveness in siRNA manufacturing by reducing purification costs and improving process performance [1][2] - The company has established itself as a leader in enzymatic technology for siRNA manufacturing, with increasing customer interest in incorporating this technology into drug development [2][3] - Codexis showcased a machine learning tool that significantly enhances the ligation process for siRNA production, improving efficiency and reducing development time [4][6] Group 1: Technology and Performance - The ECO Synthesis platform utilizes immobilized enzymes to achieve consistent process performance, with potential reductions in downstream purification steps [3][6] - Codexis' ligation processes have been validated by leading CDMOs, confirming the transferability and effectiveness of its technology in various manufacturing settings [5][7] - The company reported a coupling efficiency of over 98% and a 24% reduction in average cycle time, leading to high yields of 30 grams of siRNA per liter [6][7] Group 2: Market Position and Future Outlook - Codexis is positioned to capitalize on the growing trend towards enzymatic manufacturing solutions and onshoring initiatives, making its technology rollout timely [2][3] - The company aims to establish a GMP scale-up partnership by the end of the year, translating current momentum into tangible business growth [2][3] - The ability to control stereochemistry in oligonucleotide synthesis through the ECO Synthesis platform could enhance the therapeutic potency and market position of siRNA products [8]

分组1 - Codexis reported a quarterly loss of $0.25 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.20, and compared to a loss of $0.16 per share a year ago, indicating a significant earnings surprise of -25% [1] - The company generated revenues of $7.54 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 28.99%, and a decline from year-ago revenues of $17.07 million [2] - Codexis shares have decreased by approximately 46.3% since the beginning of the year, contrasting with the S&P 500's gain of 0.1% [3] 分组2 - The earnings outlook for Codexis is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Codexis is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $14.68 million, and for the current fiscal year, it is -$0.62 on revenues of $65.74 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Codexis belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a positive outlook for stocks within this sector [8] - Roivant Sciences Ltd., another company in the same industry, is expected to report a quarterly loss of $0.16 per share, reflecting a year-over-year change of +30.4%, with revenues projected to be $67.33 million, up 132.7% from the previous year [9]